American Heart Association (AHA)

The American Heart Association (AHA) funds cardiovascular medical research, educates consumers on healthy living and fosters appropriate cardiac care in an effort to reduce disability and deaths caused by cardiovascular disease and stroke. The AHA also is a key resource for the latest cardiology science through its journals and annual meeting.

older patient with a doctor at their house

‘Fundamental for all patients’: Exploring the benefits of palliative care for stroke survivors

Approximately 800,000 strokes occur each year in the United States alone. A majority of people survive, due in part to key advances in patient care over the years, but they often go forward without receiving the long-term help they need to recover and thrive. 

Thumbnail

New AI program delivers rapid, accurate echo video assessments

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

womanconsultation.jpg

Genetic predisposition to depression increases CVD risk in women, but not men

The heightened risks were even seen in women who were never diagnosed with a psychiatric disorder. It remains unclear why the same trend was not seen in men.

Daniel Judge, MD, director of the cardiovascular genetics program, Medical University of South Carolina, the Edwin W. and Teresa H. Rogers Endowed Chair for Cardiovascular Research, Medical University of South Carolina, presented the results of the late-breaking ATTRibute-CM study for the drug acoramidis used to treat transthyretin amyloidosis at AHA 2024.

ATTR-CM drug acoramidis, now approved by the FDA, linked to positive long-term data

Cardiovascular Business spoke with cardiologist Daniel Judge, MD, about the long-term benefits of acoramidis, a new drug therapy that just received FDA approval to treat transthyretin amyloid cardiomyopathy.

Video of Martha Gulati explaining preventive cardiology advanacements for obese patients. #AHA24 #AHA2024 #CVprev

Martha Gulati highlights 'exciting' progress in preventive cardiology

Martha Gulati, MD, spoke to Cardiovascular Business at AHA Scientific Sessions 2024 about key developments in obesity treatment and CVD prevention.

Left atrial appendage occlusion (LAAO) with the Watchman FLX device from Boston Scientific is associated with positive outcomes and limited adverse events after one year, according to new findings published in Circulation: Cardiovascular Interventions.[1] Many prior Watchman FLX studies, including PINNACLE FLX, had focused on the device’s performance in a controlled setting. The study’s authors hoped to gain a better understanding of its real-world impact by reviewing registry data from more than 97,000 U.S

LAAC with Watchman FLX reduces bleeding risks after AFib ablation

The new data, presented during AHA Scientific Sessions 2024, suggest LAAC with Boston Scientific's Watchman FLX could be a safe, effective alternative to OAC for limiting post-ablation strokes.

Immediate Past President of the American College of Cardiology (ACC) Hadley Wilson, MD, FACC, executive vice chair of Atrium Health Sanger Heart and Vascular Institute and a clinical professor of medicine at Wake Forest University School of Medicine, details the top late-breaking studies at AHA 2024. #AHA24 #AHA2024

9 key takeaways from AHA 2024 in Chicago

Hadley Wilson, MD, spoke to Cardiovascular Business at the three-day event to discuss key late-breaking studies and trends. Topics included new drug treatments, AI and much more.

artificial intelligence in cardiology

No-contact blood pressure and diabetes screening with AI shows promise

The new technology, still under development, could help physicians screen patients for diabetes and hypertension with high-speed video recordings. 

Around the web

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.